[
    "{\"step_by_step_thinking\": \"Document [1] states that tebentafusp recently became the first FDA-approved agent for metastatic uveal melanoma. Document [2] suggests that tebentafusp may become the standard of care for first-line treatment of metastatic uveal melanoma. Document [3] confirms that tebentafusp was approved by the FDA to treat patients with inoperable or metastatic forms of uveal melanoma. Document [17] reports that treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. These documents provide strong evidence that tebentafusp is effective for uveal melanoma.\", \"answer_choice\": \"A\"}"
]